Department of Defense Grants
Adult Tissue-Derived Stem Cells and Tolerance Induction in Nonhuman Primates for Vascularized Composite Allograft Transplantation
Congressionally Directed Medical Research Programs (CDMRP)
Vascularized Bone Marrow Regulates Alloresponses to Vascularized Composite Allografts
Dept. of Defense – AFIRM II
Upregulation of bone marrow compartment mediated immunomodulation for vascularized composite allografts
Congressionally Directed Medical Research Programs
Restorative Transplantation Research Cooperative Agreement
NIH Grants
Prospective observational study of HIV+ deceased donor transplant for HIV+ recipients (ongoing, recruiting)
The primary objective is to evaluation the safety of HIVDD solid organ transplantation to include kidney alone, liver alone, or simultaneous liver/kidney in HIV+ recipients.
The primary outcome is 3 year patient survival.
Randomized controlled trial of Inflixmab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (ongoing, recruiting)
The objective of this study is to determine the efficacy of intravenous infliximab administered at the time of transplantation, prior to reperfusion, on a 2-year kidney transplant survival and function.
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients (ongoing, recruiting)
The primary objectives are to evaluate impact of CCR5 blockade (maraviroc, MVC) on renal function at week 52 post-transplant, and the overall safety and tolerability of CCR5 blockade in the HIV+ kidney transplant recipient.
Basic Science Research
Bromberg (PI)
NIH 1RO1AI062765
Induction and Migration of Regulatory T Cells: Role of Lymphotoxin.
The major goals of this project are: 1.) Determine if LT regulation of Treg afferent lymphatic migration is required for suppression of Tconv in tissues and dLN; and 2.) Determine how Treg LTab - LEC LTbR interactions regulate migration.
Bromberg (PI)
NIH 1RO1AI14496-01
Lymph Node Structure and Function in Tolerance: Role of Laminins
The major goals of this project are: 1.) Determine the role of CR laminins in transplant tolerance; 2) Determine how laminins regulate HEV and CR entry of T cells and their conversion to iTreg in tolerance; and 3.) Determine how laminins regulate the migration and fate of a later cohort of naive T cells that newly enter the HEV and CR tolerant environment.
Bromberg (Co-PI and mentor for C. Colin Brinkman and Wenji Piao)
Living Legacy Foundation Transplantation Grant
The role of lymphotoxin in Treg migration and suppressor function
The major goals of this project are: 1.) If Treg migrate from blood to tissues, but cannot migrate out of tissues, does this change suppression of nonTreg in the tissues? 2.) What is the fate of non-migrated Treg and are they suppressive? and 3.) If Treg cannot migrate out of tissues, does this change suppression of nonTreg cells in the dLN?
Bromberg (Co-PI)
Living Legacy Foundation Transplantation Grant
Microbiota Structure and Transplant Outcomes: Preclinical Studies
The major goals of this project are: 1.) Determine the effects of different microbiota on allograft survival and alloimmunity; 2.) Determine how the microbiota population structure evolves during allograft survival and rejection; and 3.) Determine how transplantation, immunosuppression and antibiotics alter microbiota structure
Bromberg (Co-investigator)
National Multiple Sclerosis Society
Harnessing intra-lymph node controlled release to promote myelin-specific tolerance.
The major goals of this project are: 1.) Test if depots promote TREGS and stop or reverse progressive autoimmune disease (EAE); 2.) Decipher the local and systemic changes in myelin response that lead to tolerance; and 3.) Test if depots can stop or reverse relapsing-remitting autoimmune disease (RR-EAE).
Bromberg (Co-investigator)
VA Maryland Health Care System
Tunable Assembly of Regulatory Immune Signals to Promote Myelin-specific Tolerance
The major goals of this project are: 1.) Characterize iPEM material properties and screen in primary mouse cells and MS patient samples; 2.) Assess potency in progressive autoimmune disease (EAE) and test if tolerance is myelin-specific; 3.) Elucidate the structural and functional changes in LNs, spleen, and the CNS that lead to tolerance; and 4.) Test if tolerance is generalizable to other self-antigens using relapsing-remitting model (RR-EAE).
Bromberg (Co-investigator)
JDRF
Engineering local lymph node function to promote systemic, antigen-specific tolerance in T1D.
The major goals of this project are: 1.) Design and screen depots loaded with Rapa and T1D antigens in dendritic cell (DC) and transgenic T cell culture; 2.) Test depot efficacy in T1D mouse models during early or late stage treatment and determine the specificity of tolerance; and 3.) Elucidate the structural and functional changes in LNs, spleen, and pancreatic islets that lead to tolerance.
Bromberg (co-PI)
UMD-UMB 2017 Research and Innovation Seed Grant
Local engineering of the lymph node microenvironment in non-human primates to support translational therapies targeting autoimmunity and transplant rejection.
The goal of the present study is to demonstrate the potency of intra-lymph node (iLN) injection of microparticle (MPs) depots loaded with antigens and the immunosuppressive drugs rapamycin (Rapa) in non-human primates (NHP). Aim 1: Test the tolerogenic potential of iLN-MP to prevent responses to model antigens in NHPs. Aim 2: Assess skin graft survival and donor-specific hypo-responsiveness promoted by iLN-MPs
Bromberg (co-I)
NIBIB 1R01EB026896
Harnessing biomaterials to study the link between local lymph node function and systemic tolerance.
The major goals of the project are: 1.) Determine how local signals in LNs polarize T cell function and program systemic tolerance; 2.) Decipher the impact of signal location, delivery route, and kinetics on T cell polarization; 3.) Compare the local structure and function of depot-treated LNs to distal LNs, spleen, and CNS; and 4.) Test if link between local function and systemic tolerance is generalizable to other self-antigens.
Clinical Science Research
Bromberg (site PI)
NIAID U01 AI063594
CTOT-19- Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy
For Deceased Donor Kidney Transplant Recipients
The objective of the study is to determine the efficacy of intravenous infliximab administered at the time of transplantation, prior to reperfusion, on 2-year kidney transplant survival and function.
Bromberg (site PI)
NIAID 1R01AI123342
Innate B Cell Immunity and Antibody-Mediated Rejection of Human Kidney Allografts
The goal of the present study is to further investigate the role of Nabs IgG in the outcome of kidney transplants in a large group of patients treated at multiple centers. Our main objective is to assess the value of serum IgG Nabs as a biomarker for rejection (ABMR) and ultimately graft loss following kidney transplantation. We will also examine whether the development of IgG Nabs correlate with anti-HLA antibodies and DSA.
Bromberg (PI)
1 U01 DK116095-01
U Maryland Mid-Atlantic APOLLO Research Network Omic and Clinical Center
The major goals of this project are to investigate the following hypotheses:
- Functional APOL1 risk alleles in AA can activate and/or promote pathophysiologic pathways leading to maladaptive responses to renal injury resulting in increased susceptibility to albuminuria, hypertension, progressive CKD and/or ESRD in kidney donors
- Among allograft recipients, kidney specific APOL1 risk alleles can activate and/or promote pathophysiologic pathways leading to maladaptive responses to renal injury and increased risk of albuminuria, progressive CKD and/or renal allograft failure
- APOL1 risk alleles can activate and/or promote pathophysiologic pathways leading to increased blood pressure and cardiovascular (CV) events in renal allograft donors and recipients.
